



Cancer Mission

Risultati e bandi del 2023

Giovanni Apolone

Direttore Scientifico– INT



Presidente Eletto – OECI

Coordinatore progetti call 2021 02-02, 2022 01-02

Outline

- Cancer Mission
- Le call 2021-2022
- Performance partecipazione Italia in CM
- Le call del 2023
- L'esperienza di INT
- Qualche riflessione

Cancer Mission



13 Recommendations for bold actions

- 1 Launch **UNCAN.eu** – a European Initiative to Understand Cancer
- 2 Develop an EU-wide research programme to identify (poly-) genic risk scores
- 3 Support the development and implementation of effective cancer prevention strategies and policies within Member States and the EU
- 4 Optimise existing screening programmes and develop novel approaches for screening and early detection
- 5 Advance and implement personalised medicine approaches for all cancer patients in Europe
- 6 Develop an EU-wide research programme on early diagnostic and minimally invasive treatment technologies
- 7 Develop an EU-wide research programme and policy support to improve the quality of life of cancer patients and survivors, family members and carers, and all persons with an increased risk of cancer
- 8 Create a European Cancer Patient Digital Centre where cancer patients and survivors can deposit and share their data for personalised care
- 9 Achieve Cancer Health Equity in the EU across the continuum of the disease
- 10 Set up a network of Comprehensive Cancer Infrastructures within and across all EU Member States to increase quality of research and care
- 11 Childhood cancers and cancers in adolescents and young adults: cure more and cure better
- 12 Accelerate innovation and implementation of new technologies and create Oncology-focused Living Labs to conquer cancer
- 13 Transform cancer culture, communication and capacity building



Le Call della CM

	2021	2022	2023
No.	4	5	4
Budget	128.65	126	110.68

2021 call topics general statistics

Call opening: 22.12.2021

Call closure: 26.04.2022

TOPIC ID	Action Type	Call Indicative Budget (M EUR)	Received proposals	Funded proposals
HORIZON-MISS-2021-CANCER-02-01	RIA	60.00	78	6
HORIZON-MISS-2021-CANCER-02-02	RIA	11.00	4	1
HORIZON-MISS-2021-CANCER-02-03	RIA	54.60	24	5
TOTAL		125.60	106	12

HORIZON-MISS-2021-CANCER-02-01:
Develop new methods and technologies for screening and early detection

HORIZON-MISS-2021-CANCER-02-02:
Develop and validate a set of quality of life measures for cancer patients and survivors

HORIZON-MISS-2021-CANCER-02-03:
Better understand healthy versus cancer cells at individual and population level

Funded proposals/projects starting their implementation in 2023!

Further publicly available information can be found via [CORDIS \(EU Research Results platform\)](#)

2022 CALL TOPICS – General Statistics

Via **webex** **22 call topics**
general statistics

Call opening: 24.05.2022
Call closure: 07.09.2022

TOPIC ID	Action Type	Call Indicative Budget (M EUR)	Received proposals	Number of proposals retained for funding
HORIZON-MISS-2022-CANCER-01-01	RIA	50.00	15	6
HORIZON-MISS-2022-CANCER-01-02	CSA	10.00	2	1
HORIZON-MISS-2022-CANCER-01-03	RIA	60.00	15	12
HORIZON-MISS-2022-CANCER-01-04	CSA	3.00	0	0
HORIZON-MISS-2022-CANCER-01-05	CSA	3.00	2	1
TOTAL		126.00	34	20



HORIZON-MISS-2022-CANCER-01-01:
Improving and upscaling primary prevention of cancer through implementation research

HORIZON-MISS-2022-CANCER-01-02:
Strengthening research capacities of comprehensive cancer infrastructures

HORIZON-MISS-2022-CANCER-01-03:
Pragmatic clinical trials to optimise treatment for cancer patients

HORIZON-MISS-2022-CANCER-01-04:
Towards the creation of a European Cancer Patient Digital Centre

HORIZON-MISS-2022-CANCER-01-05:
Creation of national cancer mission hubs to support the implementation of the Mission on Cancer

Proposals retained for funding are currently at Grant Agreement Preparation phase!

MISSION CANCER 2021+2022 | I primi bandi

8 BANDI

- HORIZON-MISS-2021-UNCAN-01-01
- HORIZON-MISS-2021-CANCER-02-01
- HORIZON-MISS-2021-CANCER-02-02
- HORIZON-MISS-2021-CANCER-02-03
- HORIZON-MISS-2022-CANCER-01-01
- HORIZON-MISS-2022-CANCER-01-02
- HORIZON-MISS-2022-CANCER-01-03
- HORIZON-MISS-2022-CANCER-01-05

PERFORMANCE IT

TASSO DI SUCCESSO IT #

18 %



TASSO DI SUCCESSO IT €

14 %



MISSION CANCER 2021 + 2022 | COMPETIZIONE EUROPEA – TOP SEVEN



Paesi	#Partecipazione	€ Contributo finanziario	#Rientro	€Rientro
BE	79	46.727.357 €	10%	13%
ES	106	41.518.409 €	13%	12%
FR	70	39.306.305 €	8%	10.9%
IT	81	38.028.979 €	10%	10.6%
DE	72	37.827.567 €	9%	10.5%
IL	31	31.509.835 €	4%	9%
EL	41	22.372.868 €	5%	6%

ITALIA #
2^o posto

ITALIA €
4^o posto

MISSION CANCER 2021 + 2022 | COORDINAMENTI –TOP SEVEN




Paesi	#Coordinamenti	€ Contributo finanziario
BE	6	19.771.322 €
IT	7	15.812.839 €
IL	6	14.359.700 €
EL	6	8.477.333 €
FR	5	6.891.748 €
ES	5	5.757.679 €
DE	3	4.687.948 €

ITALIA #
1^o posto

ITALIA €
2^o posto

MISSION CANCER 2021 + 2022 | PERFORMANCE per TOPIC (partecipazioni | Eu Contrib)



Le call del 2023

Call - Research and Innovation actions supporting the implementation of the Mission on Cancer

HORIZON-MISS-2023-CANCER-01

Topics	Type of Action	Budgets (EUR million)	Expected EU contribution per project (EUR million) ²	Indicative number of projects expected to be funded
		2023		
Opening: 12 Jan 2023 Deadline(s): 12 Apr 2023				
HORIZON-MISS-2023-CANCER-01-01	RIA	36.68 ³	7.00 to 12.00	4
HORIZON-MISS-2023-CANCER-01-02	RIA	25.00 ⁴	4.00 to 6.00	5
HORIZON-MISS-2023-CANCER-01-03	RIA	43.00 ⁵	6.00 to 8.00	7
HORIZON-MISS-2023-CANCER-01-04	IA	6.00 ⁶	Around 6.00	1
Overall indicative budget		110.68		

Le call del 2023:Titoli


HORIZON-MISS-2023-CANCER-01-01: Addressing poorly-understood tumour-host interactions to enhance immune system-centred treatment and care interventions in childhood, adolescent, adult and elderly cancer patients.

HORIZON-MISS-2023-CANCER-01-02: Enhance primary cancer prevention through sustainable behavioural change

HORIZON-MISS-2023-CANCER-01-03: Pragmatic clinical trials on minimally invasive diagnostics

HORIZON-MISS-2023-CANCER-01-04: Establish best practices and tools to improve the quality of life for childhood cancer patients, survivors and their families in European regions

INT EU funded projects



INT - PROGETTI MISSION CANCER FINANZIATI

Principal Investigator	Finanziamento	Acronimo	Ruolo	Titolo progetto
G. APOLONE	€ 1.913.271,00	EUonQOL	Coordinatore	Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe
A. FERRARI	€ 200.003,00	MELCAYA	Partner	Novel health care strategies for melanoma in children, adolescents and young adults
F. DE BRAUD *	€ 351.875,00	CCI4EU	Partner	Comprehensive Cancer Infrastructures for Europe
G. APOLONE	€ 127.000,00	ECHOS	Partner	Establishing of Cancer Mission Hubs: Networks and Synergies
G. PROCOPIO	€ 371.250,00	CARE1	Partner	First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma
A. GRONCHI	€ 108.750,00	STREXIT	Partner	A pragmatic clinical study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with high risk retroperitoneal sarcoma

* Coordinato da G.Apolone, per conto di OECl

COMPREHENSIVE CANCER INFRASTRUCTURE IN EUROPE (CCI4EU)



Call: HORIZON-MISS-2022-CANCER-01 **Topic:** HORIZON-MISS-2022-CANCER-01-02 **Type of action:** CSA

Project Title: Comprehensive Cancer Infrastructure in Europe (CCI4EU)

Start/End Date: 1/05/2023 – 30/04/2026


Total Requested Budget: 9.984.080,00€

Coordination: OECI (G.Apolone)

European initiative, implemented in all Member States, based on a capacity building programme (CBP), will help reduce inequalities, in the context of other actions ongoing, such as *CRANE*, *JANE* and *UNCAN*.

The CSA will implement the following steps:


- define CCI Maturity Model including quality indicators;
- profile the CCIs in each MS and a few ACs in terms of CCI presence and levels of maturity; design tailored CBP interventions, giving priority to MSs without any CCI;
- deliver online training courses open to teams in all MSs and ACs, implement targeted onsite interventions;
- scale up and sustain development; disseminate, exploit and report results.




EUonQOL: measuring what matter for cancer patients

Call Topic: HORIZON-MISS-2021- CANCER-02-02

Starting date: 1 January 2023
 End date: 31 December 2026
 Duration: 48 months
 Costs: € 11,081,626.00
 EU contribution: € 10,607,311.00
 Partners: 23
 Third parties: 28



The overall goal is to be instrumental to the progress of the Mission on Cancer plan, with the specific aim of *developing, piloting, validating, and exploiting* the European Oncology Quality of Life toolkit (EUonQoL-Kit) among European cancer patients and survivors. The project will be based on participatory co-design principles through the involvement of patients and their caregivers



13 Countries

Austria
 Belgium
 Bulgaria
 Denmark
 Estonia
 France
 Germany
 Italy
 Norway
 Romania
 Spain
 The Netherlands
 United Kingdom

Coordinator

Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy

26 Partner/Affiliated/Associated Partner

Medical University of Innsbruck (MUI)
 Digital Institute For Cancer Outcomes Research (DIGICORE)
 European Organisation for Research and Treatment of Cancer AISBL (EORTC)
 European Association of Palliative Care (EAPC)
 European Cancer Organisation (ECO)
 Organisation of European Cancer Institutes (OECI)
 Association of Cancer Patients and Friends (APOZ)
 Region Hovedstaden (RH)
 Sporedata OU (SPOREDATA)
 Institut Curie (CURIE)
 Institut Gustave Roussy (GR)
 Unicancer (UNICANCER)
 Deutsches Krebsforschungszentrum Heidelberg (DFKZ)
 Alleanza Contro il Cancro (ACC)
 Federazione Italiana delle Associazioni di Volontariato in Oncologia (FAVO)
 Istituto Europeo di Oncologia (IEO)
 Istituto Nazionale Tumori Fondazione Pascale (INT-NA)
 Istituti Fisioterapici Ospitalieri (IFO)
 Università Degli Studi di Milano (UMIL)
 Oslo Universitetssykehus HF (OUS)
 Asociatiilor Bolnavilor de Cancer (FABC)
 Fundacio Institut Mar d'Investigacions Mediques (IMIM)
 Stichting Het Nederlands Kanker Instituut-Anton (NKI)
 Stichting Nederlands Instituut Voor Onderzoek Van De Gezondheidszorg (NIVEL)
 University of Leeds (UNIVLEEDS)
 Leeds Teaching Hospital Trust's (LTHT)

INT: qualche riflessione

- Notevole incremento della partecipazione a call EU negli ultimi 3 anni
 - Effetto Piano Strategico Ricerca
 - Presenza di un continuum della ricerca
 - Presenza in molti «tavoli» europei
- Aumento successo come partner e come coordinator
 - Massa critica e qualità ricercatori
 - Qualità e potenziamento Grant Office
 - Acquisizione società esterna di supporto
- Impatto (negativo) su uffici amministrativi INT